In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

Hey, AbbVie, what do you say? The Cubs are gonna strike out cancer today. | A new partnership between the Chicago-based ...

In the wake of sweeping cuts at the FDA’s Office of Prescription Drug Promotion (OPDP), Sen. | In the wake of sweeping cuts ...

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

Astellas is banging the drum for patient advocacy organizations (PAOs) again. | Astellas is banging the drum for patient ...